CHMP recommends marketing withdrawal for bufexamac
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended that products containing the non-steroidal anti-inflammatory (NSAID) bufexamac be withdrawn due to risk of contact allergic reactions.